ERBB2 and breast carcinoma: We know that biomarkers can be classified into predictive biomarkers (e.g., HER2 that predicts response to trastuzumab in breast cancer); prognostic biomarkers and; diagnostic biomarker (e.g., stool DNA testing for colorectal-cancer) [79].